Program Description
Biologic oncology drugs are the current standard treatment for many forms of cancer; however, they are much more expensive to develop and manufacture than traditional oncology drugs. This high cost imposes a substantial burden on the United States health care system and creates patient access barriers. Biosimilars have been developed as alternatives, potentially lowering costs and increasing access to state-of-the-art care. This comes at a critical time when treatment costs and the incidence of cancer is rising. Thus, the impact of affordable options on the national health care economics may be profound. Managed care pharmacists must ensure they are up-to-date on these cost-effective treatment options to enhance the well-being of patients and decrease their financial burden. This activity will educate managed care professionals about the economic impact of oncology biosimilars, review the necessary considerations for implementation of oncology biosimilars into formularies and clinical pathways, and discuss managed care strategies for encouraging the adoption of oncology biosimilars into clinical practice.
Target audience: Health-system, oncology, and managed care pharmacists
Type of activity: Application
Release date: December 19, 2022
Expiration date: February 19, 2023
Time to complete activity: 1.0 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the economic consideration and the role of biosimilars in reducing overall cost of cancer treatment
- Analyze the considerations for the inclusion of oncology biosimilars into formulary and clinical pathways
- Investigate payer strategies to manage uptake of biosimilars in value-based care systems to improve patient outcomes
YuQian Liu, PharmD
Senior Director
Specialty Clinical Solutions
Magellan Rx Management
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-22-577-L01-P. The activity is available for CE credit through February 19, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
YuQian Liu, PharmD, has the following financial relationships with commercial interests to disclose:
Other Support: Employee of Magelian Rx Management
The following contributors have no relevant financial relationships with commercial interests to disclose:
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Karleen Melody, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms